Skip to main content

Table 2 Multivariate analysisa for no remission according to each clinical index

From: Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study

  OR 95% CI P-value
DAS28-ESR, no remission
 Disease duration, years 1.02 1.00–1.05 0.10
 Positive for rheumatoid factor 2.18 1.47–3.22 < 0.00
 Previous use of bDMARDs 4.37 2.00–9.54 < 0.00
 Presence of FAA 3.43 2.01–5.84 < 0.00
DAS28-CRP, no remission
 Presence of lung disease 3.53 1.08–11.53 0.04
 Positive for rheumatoid factor 1.64 1.18–2.29 < 0.00
 Previous use of bDMARDs 4.25 2.47–7.31 < 0.00
 Presence of FAA 3.59 2.43–5.33 < 0.00
SDAI, no remission
 Previous use of bDMARDs 6.77 2.13–21.5 < 0.00
 Presence of FAA 6.33 2.75–14.6 < 0.00
CDAI, no remission
 Previous use of bDMARDs 5.94 1.44–24.49 < 0.00
 Presence of FAA 7.59 2.37–24.33 < 0.00
RAPID, no remission
 Use of MTX 2.6 0.94–7.23 0.07
 Previous use of bDMARDs 8.22 2.59–26.11 < 0.00
 Presence of FAA 5.57 2.69–11.52 < 0.00
  1. aFactors known to be associated with remission such as age, disease duration, the positivity of RF, positivity of anti-cyclic citrullinated peptide, the existence of lung disease, use of MTX, previous use of bDMARDs were included for multivariate logistic regression analysis